Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SCYNEXIS, Inc. - Common Stock (NQ:SCYX)

0.6220 -0.0104 (-1.64%)
Streaming Delayed Price Updated: 12:35 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SCYNEXIS, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
22 Stocks Moving in Wednesday's Pre-Market Session ↗
Gainers Stealth BioTherapeutics Corp (NASDAQ: MITO) rose 37.2% to $1.99 in pre-market trading after the company said it received orphan drug designation from the European... 
Via Benzinga
News headline image
Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates ↗
The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive... 
Via Benzinga
News headline image
24 Stocks Moving in Tuesday's Pre-Market Session ↗
Gainers Vertex Energy, Inc. (NASDAQ: VTNR) rose 43.5% to $11.21 in pre-market trading. Vertex Energy, shares jumped around 96% on Friday on continued momentum after the company... 
Via Benzinga
News headline image
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes ↗
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers Strongbridge Biopharma (NASDAQ:SBBP) stock moved upwards by 14.1% to $2.75 during Monday's pre-market session. The market value of their outstanding shares is... 
Via Benzinga
News headline image
Scynexis Raises $60M Via Term Loan Ahead Of Expected Approval Of Vaginal Yeast Infection Treatment ↗
Scynexis Inc (NASDAQ: SCYX) is taking out a loan to ensure it can hit the ground running for a potential commercial launch of ibrexafungerp for vaginal yeast infections... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.